Aleglitazar

Aleglitazar

Aleglitazar

Chemical compound

Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]

Quick Facts Names, Identifiers ...

References

  1. [1]
    "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
  2. [2]
    "Roche halts diabetes drug trial in blow to pipeline". Roche. 2013-07-10. Retrieved 2013-07-10.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Aleglitazar, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.